From new partnerships and launches, here are six developments from Globus Medical so far in 2025.
1. OsteoCentric Technologies entered into a non-exclusive licensing agreement with Globus Medical. OsteoCentric’s MIS Bone Preservation Tapping Technology & Instant Interlocking Thread-form is the first implant-to-bone interface capable of sustaining primary implant stability over time.
2. Globus Medical launched its Cohere anterior lumbar interbody fusion spacer and Modulus ALIF blades. The Cohere space is the first porous polyether-ether-ketone interbody spacer for anterior lumbar interbody fusion surgery. The Modulus device is an extension of Globus’ existing Modulus ALIF interbody spacer system.
3. Globus Medial completed its acquisition of Nevro, a spinal cord stimulator company. The deal was first announced in February, and Nevro was valued at $250 million. Nevro employs HFX spinal cord stimulation, which is used in its Senza SCS system. The company also offers minimally invasive treatments for chronic sacroiliac joint pain.
4. Globus Medical CEO Daniel Scavilla’s salary rose to $4.8 million in 2024, according to the company’s April 25 Securities and Exchange Commission proxy filing.
5. Globus Medical’s first quarter sales decreased 1.4% year over year, according to financial results posted May 8. The company also returned to debt-free status after paying off the rest of the $450 million debt from its NuVasive merger.6. Globus Medical’s board of directors authorized a share repurchase program of up to $500 million of the company’s outstanding common stock.